|
1.
|
Melegari M, Scaglioni PP and Wands JR:
Cloning and characterization of a novel hepatitis B virus x binding
protein that inhibits viral replication. J Virol. 72:1737–1743.
1998.PubMed/NCBI
|
|
2.
|
Lok AS: Hepatitis B infection:
pathogenesis and management. J Hepatol. 32:89–97. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Fujii R, Zhu C, Wen Y, Marusawa H,
Bailly-Maitre B, Matsuzawa S, Zhang H, Kim Y, Bennett CF, Jiang W
and Reed JC: HBXIP, cellular target of hepatitis B virus
oncoprotein, is a regulator of centrosome dynamics and cytokinesis.
Cancer Res. 66:9099–9107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Wen Y, Golubkov VS, Strongin AY, Jiang W
and Reed JC: Interaction of hepatitis B viral oncoprotein with
cellular target HBXIP dysregulates centrosome dynamics and mitotic
spindle formation. J Biol Chem. 283:2793–2803. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bar-Peled L, Schweitzer LD, Zoncu R and
Sabatini DM: Ragulator is a GEF for the Rag GTPases that signal
amino acid levels to mTORC1. Cell. 150:1196–1208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Liu S, Li L, Zhang Y, Zhang Y, Zhao Y, You
X, Lin Z, Zhang X and Ye L: The oncoprotein HBXIP uses two pathways
to up-regulate S100A4 in promotion of growth and migration of
breast cancer cells. J Biol Chem. 287:30228–30239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue
L, Bai X, Zhang Z, Zhang W, Zhang X and Ye L: miR-520b regulates
migration of breast cancer cells by targeting hepatitis B
X-interacting protein and interleukin-8. J Biol Chem.
286:13714–13722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Zhang H, Kobayashi R, Galaktionov K and
Beach D: p19Skp1 and p45Skp2 are essential elements of the cyclin
A-CDK2 S phase kinase. Cell. 82:915–925. 1995. View Article : Google Scholar
|
|
9.
|
Kurland JF and Tansey WP: Crashing waves
of destruction: the cell cycle and APC(Cdh1) regulation of
SCF(Skp2). Cancer Cell. 5:305–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Suzuki S, Fukasawa H, Misaki T, Togawa A,
Ohashi N, Kitagawa K, Kotake Y, Liu N, Niida H, Nakayama K,
Nakayama KI, Yamamoto T and Kitagawa M: The amelioration of renal
damage in Skp2-deficient mice canceled by p27 Kip1 deficiency in
Skp2−/−p27−/−mice. PLoS One. 7:e362492012.PubMed/NCBI
|
|
11.
|
Lin HK, Wang G, Chen Z, Teruya-Feldstein
J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer
S, Tempst P and Pandolfi PP: Phosphorylation-dependent regulation
of cytosolic localization and oncogenic function of Skp2 by
Akt/PKB. Nat Cell Biol. 11:420–432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chan CH, Lee SW, Li CF, Wang J, Yang WL,
Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, Hung MC, Pandolfi PP
and Lin HK: Deciphering the transcriptional complex critical for
RhoA gene expression and cancer metastasis. Nat Cell Biol.
12:457–467. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Inuzuka H, Gao D, Finley LW, Yang W, Wan
L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP,
Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, Pandolfi PP and
Wei W: Acetylation-dependent regulation of Skp2 function. Cell.
150:179–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Cardozo T and Pagano M: The SCF ubiquitin
ligase: insights into a molecular machine. Nat Rev Mol Cell Biol.
5:739–751. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bretones G, Acosta JC, Caraballo JM,
Ferrándiz N, Gómez-Casares MT, Albajar M, Blanco R, Ruiz P, Hung
WC, Albero MP, Perez-Roger I and León J: SKP2 oncogene is a direct
MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in
human leukemia cells. J Biol Chem. 286:9815–9825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Einama T, Kagata Y, Tsuda H, Morita D,
Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y,
Matsubara O and Hatsuse K: High-level Skp2 expression in pancreatic
ductal adenocarcinoma: correlation with the extent of lymph node
metastasis, higher histological grade, and poorer patient outcome.
Pancreas. 32:376–381. 2006. View Article : Google Scholar
|
|
17.
|
Hung WC, Tseng WL, Shiea J and Chang HC:
Skp2 overexpression increases the expression of MMP-2 and MMP-9 and
invasion of lung cancer cells. Cancer Lett. 288:156–161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Li CF, Wang JM, Kang HY, Huang CK, Wang
JW, Fang FM, Wang YH, Wu WR, Li SH, Yu SC, Lee JC, Lan J, Shiue YL,
Wu LC and Huang HY: Characterization of gene amplification-driven
SKP2 overexpression in myxofibrosarcoma: potential implications in
tumor progression and therapeutics. Clin Cancer Res. 18:1598–1610.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lim MS, Adamson A, Lin Z, Perez-Ordonez B,
Jordan RC, Tripp S, Perkins SL and Elenitoba-Johnson KS: Expression
of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma:
correlation with p27(Kip1) and proliferation index. Blood.
100:2950–2956. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lu M, Zhao Y, Xu F, Wang Y, Xiang J and
Chen D: The expression and prognosis of FOXO3a and Skp2 in human
ovarian cancer. Med Oncol. 29:3409–3415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Masuda TA, Inoue H, Sonoda H, Mine S,
Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and
biological significance of S-phase kinase-associated protein 2
(Skp2) gene expression in gastric carcinoma: modulation of
malignant phenotype by Skp2 overexpression, possibly via p27
proteolysis. Cancer Res. 62:3819–3825. 2002.
|
|
22.
|
Shapira M, Ben-Izhak O, Linn S, Futerman
B, Minkov I and Hershko DD: The prognostic impact of the ubiquitin
ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer.
103:1336–1346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shigemasa K, Gu L, O’Brien TJ and Ohama K:
Skp2 over-expression is a prognostic factor in patients with
ovarian adenocarcinoma. Clin Cancer Res. 9:1756–1763.
2003.PubMed/NCBI
|
|
24.
|
Sonoda H, Inoue H, Ogawa K, Utsunomiya T,
Masuda TA and Mori M: Significance of skp2 expression in primary
breast cancer. Clin Cancer Res. 12:1215–1220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Traub F, Mengel M, Luck HJ, Kreipe HH and
von Wasielewski R: Prognostic impact of Skp2 and p27 in human
breast cancer. Breast Cancer Res Treat. 99:185–191. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wang Z, Gao D, Fukushima H, Inuzuka H, Liu
P, Wan L, Sarkar FH and Wei W: Skp2: a novel potential therapeutic
target for prostate cancer. Biochim Biophys Acta. 1825:11–17.
2012.PubMed/NCBI
|
|
27.
|
Shapira M, Kakiashvili E, Rosenberg T and
Hershko DD: The mTOR inhibitor rapamycin down-regulates the
expression of the ubiquitin ligase subunit Skp2 in breast cancer
cells. Breast Cancer Res. 8:R462006. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zhang X, Dong N, Yin L, Cai N, Ma H, You
J, Zhang H, Wang H, He R and Ye L: Hepatitis B virus X protein
upregulates survivin expression in hepatoma tissues. J Med Virol.
77:374–381. 2005. View Article : Google Scholar
|
|
29.
|
Al-Alem L, Southard RC, Kilgore MW and
Curry TE: Specific thiazolidinediones inhibit ovarian cancer cell
line proliferation and cause cell cycle arrest in a PPARgamma
independent manner. PLoS One. 6:e161792011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Liang M, Liang YY, Wrighton K,
Ungermannova D, Wang XP, Brunicardi FC, Liu X, Feng XH and Lin X:
Ubiquitination and proteolysis of cancer-derived Smad4 mutants by
SCFSkp2. Mol Cell Biol. 24:7524–7537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Nelson JD, Denisenko O and Bomsztyk K:
Protocol for the fast chromatin immunoprecipitation (ChIP) method.
Nat Protoc. 1:179–185. 2006. View Article : Google Scholar
|
|
32.
|
Hu D, Liu W, Wu G and Wan Y: Nuclear
translocation of Skp2 facilitates its destruction in response to
TGFbeta signaling. Cell Cycle. 10:285–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wang FZ, Sha L, Ye LH and Zhang XD:
Promotion of cell proliferation by HBXIP via upregulation of human
telomerase reverse transcriptase in human mesenchymal stem cells.
Acta Pharmacol Sin. 29:83–89. 2008. View Article : Google Scholar
|
|
34.
|
Davie JR, He S, Li L, Sekhavat A, Espino
P, Drobic B, Dunn KL, Sun JM, Chen HY, Yu J, Pritchard S and Wang
X: Nuclear organization and chromatin dynamics - Sp1, Sp3 and
histone deacetylases. Adv Enzyme Regul. 48:189–208. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Zheng Y, Ritzenthaler JD, Sun X, Roman J
and Han S: Prostaglandin E2 stimulates human lung carcinoma cell
growth through induction of integrin-linked kinase: the involvement
of EP4 and Sp1. Cancer Res. 69:896–904. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Kong LM, Liao CG, Chen L, Yang HS, Zhang
SH, Zhang Z, Bian HJ, Xing JL and Chen ZN: Promoter hypomethylation
up-regulates CD147 expression through increasing Sp1 binding and
associates with poor prognosis in human hepatocellular carcinoma. J
Cell Mol Med. 15:1415–1428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Chuang JY, Wu CH, Lai MD, Chang WC and
Hung JJ: Overexpression of Sp1 leads to p53-dependent apoptosis in
cancer cells. Int J Cancer. 125:2066–2076. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Previdi S, Malek A, Albertini V, Riva C,
Capella C, Broggini M, Carbone GM, Rohr J and Catapano CV:
Inhibition of Sp1-dependent transcription and antitumor activity of
the new aureolic acid analogues mithramycin SDK and SK in human
ovarian cancer xenografts. Gynecol Oncol. 118:182–188. 2010.
View Article : Google Scholar : PubMed/NCBI
|
